Media

Latest news

Press Releases

SEE ALL
November 06, 2025

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026 Pivotal trial enrollment completed in October; confirmatory trial open and enrolling  New 12-month analysis shows all participants demonstrate improved functional
October 30, 2025

REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program

Patients treated with RGX-202 demonstrate consistent, robust microdystrophin expression and functional improvement compared to natural history in Phase I/II portion of AFFINITY DUCHENNE ® trial supporting potential approval via the accelerated approval pathway REGENXBIO continues to enroll patients
October 29, 2025

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

ROCKVILLE, Md. , Oct. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, November 6 , at 8:00 a.m. ET to discuss its financial results for the third quarter ended September 30, 2025 , and operational highlights.

Presentations & Publications

SEE ALL
October 17, 2025

Suprachoroidal surabgene lomparvovec (sura-vec, ABBV-RGX-314): First time 2-year results in non-proliferative diabetic retinopathy 

Charles C. Wykoff, M.D., PhD, Retina Consultants of Texas
October 07, 2025

RGX-202, an Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy: Interim Clinical Data 
 

REGENXBIO
September 05, 2025

CAMPSIITE® Phase I/II/III: Interim clinical update of clemidsogene lanparvovec (RGX-121), an investigational gene therapy for treatment of neuronopathic mucopolysaccharidosis type II (MPS II)

Roberto Giugliani, M.D., Ph.D., Professor, Department of Genetics, UFRGS, Medical Genetics Service, HCPA, Porto Alegre, Brazil